Hyperfine, Inc. filings document a Nasdaq-listed medical device company built around the Swoop® portable MR brain imaging system and related Optive AI™ software. Its Form 8-K reports cover operating results, business updates, preliminary unaudited financial information, investor presentations, and material definitive agreements, including a senior secured term loan facility used for working capital and general corporate purposes.
Proxy materials describe annual meeting matters, governance procedures, and shareholder voting. The filing record also identifies HYPR Class A common stock registered on Nasdaq and provides capital-structure and corporate-governance disclosures tied to commercialization of portable brain MRI.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 3,568,038 shares of Hyperfine Inc common stock, representing 4.34% of the class as of the reported date. Vanguard reports no sole voting or dispositive power, with all voting and dispositive authority shared.
The filing notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries or business divisions are expected to report beneficial ownership separately. Vanguard certifies the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Hyperfine.
Hyperfine, Inc. reported preliminary, unaudited financial results for the quarter and year ended December 31, 2025. The company estimates total revenue of approximately $5.3 million for the fourth quarter of 2025 and approximately $13.5 million for the full fiscal year 2025, with estimated cash and cash equivalents of about $35.1 million as of December 31, 2025. These figures are based on management’s current information, may change as year-end financial statements are completed, and have not been audited or reviewed by the independent registered public accounting firm. Hyperfine also furnished a press release and an updated investor presentation dated January 12, 2026, which it may use in ongoing investor and corporate communications.
Hyperfine, Inc. (HYPR) Chief Operating Officer reported a small insider sale of Class A common stock. On 11/19/2025, the officer sold 1,405 shares at a price of $1.08 per share. After this transaction, the officer beneficially owns 379,657 shares of Hyperfine Class A common stock in direct ownership form.
The company states that the sale was made to cover tax withholding obligations triggered by the vesting of restricted stock units granted on March 28, 2022 and April 28, 2022 under a “sell to cover” provision in the RSU agreement. This means the shares were sold automatically to pay taxes due when the RSUs vested, rather than as a discretionary open-market sale.
Hyperfine, Inc. filed its Q3 2025 report, showing modest revenue softness and continued investment in product and market expansion. Revenue was $3.4M for the quarter, down slightly from $3.6M a year ago, with gross margin of $1.8M. Net loss was $11.0M versus $10.3M last year, and operating expenses totaled $10.8M.
Cash and cash equivalents were $21.6M as of September 30, 2025, compared with $37.6M at year-end 2024. Operating cash outflow for the first nine months was $22.7M. During 2025, the company raised capital via a February registered direct offering ($6.0M gross) with accompanying warrants and an at-the-market program. After quarter-end, it completed an underwritten public offering totaling $20.1M gross (approximately $18.4M net).
Product development advanced with FDA 510(k) clearance in May 2025 for the Optive AI software and next‑generation Swoop system, and August 2025 CE Mark/UKCA approvals. Shares outstanding were 82,113,369 Class A and 15,055,288 Class B as of November 3, 2025.
Hyperfine, Inc. furnished an 8-K announcing its third-quarter 2025 results. The company reported results for the quarter ended September 30, 2025 and provided a business update via a press release furnished as Exhibit 99.1 under Item 2.02.
The filing lists Hyperfine’s Class A common stock (HYPR) on The Nasdaq Stock Market LLC. The press release is furnished, not filed, and is incorporated only by specific reference.
Hyperfine, Inc. launched a primary offering of 14,000,000 shares of Class A common stock at $1.25 per share under a prospectus supplement. Gross proceeds are $17.5 million, with underwriting discounts of $1.15 million and estimated net proceeds of approximately $16.0 million after offering expenses.
The company granted the underwriter a 30‑day option to purchase up to 2,100,000 additional shares. If exercised in full, total net proceeds are estimated at approximately $18.4 million. Hyperfine plans to use the cash for working capital and general corporate purposes, including commercial, manufacturing, and R&D activities. Delivery of shares is expected on or about October 17, 2025, with Lake Street as sole book‑runner.
Hyperfine also provided preliminary Q3 2025 figures: $3.4 million in estimated total revenue and $21.6 million in estimated cash and cash equivalents as of September 30, 2025.
Hyperfine, Inc. priced an underwritten public offering of 14,000,000 shares of Class A common stock at $1.25 per share, for expected gross proceeds of approximately $17.5 million before fees and expenses. The underwriter, Lake Street Capital Markets, LLC, has a 30-day option to purchase up to 2,100,000 additional shares. All shares are being sold by the company, and the offering is being made via a prospectus supplement under the company’s effective Form S-3 shelf registration.
The offering is expected to close on or about October 17, 2025, subject to customary conditions. Underwriting discounts are 7.0% on the first $10 million of gross proceeds and 6.0% on any amount above that, and the company will reimburse certain underwriter expenses up to $125,000. The company agreed to a 90-day no-issuance covenant, and directors and executive officers agreed to 60-day lock-ups.
Hyperfine, Inc. (HYPR) launched a primary offering of Class A common stock and, in lieu of shares to certain investors, pre-funded warrants under its effective S-3 shelf. Lake Street is acting as sole book-runner, and the underwriters have a 15% option for additional securities.
The company intends to use proceeds for working capital and general corporate purposes, including commercial, manufacturing, and R&D activities. Pre-funded warrants are priced at the share offering price minus $0.0001 and carry a $0.0001 exercise price, are not exchange-listed, and include 4.99% or 9.99% beneficial ownership limits (adjustable with notice). Company lock-up is 90 days; directors and officers are subject to 60 days.
Management disclosed preliminary Q3 2025 revenue of approximately $3.4 million and cash and cash equivalents of approximately $21.6 million as of September 30, 2025. HYPR last closed at $2.05 on October 14, 2025. Shares outstanding were 63,525,713 Class A and 15,055,288 Class B as of June 30, 2025.
Hyperfine (HYPR) furnished preliminary, unaudited Q3 2025 results. For the quarter ended September 30, 2025, the company estimated total revenue of approximately $3.4 million. Cash and cash equivalents were approximately $21.6 million as of September 30, 2025.
Management emphasized these figures are preliminary, subject to change, and have not been audited, reviewed, or compiled by the independent registered public accounting firm. Complete quarterly results will be included in the Quarterly Report on Form 10‑Q for the quarter ended September 30, 2025.
The company also issued a press release and updated its Investor Presentation, furnished as Exhibits 99.1 and 99.2. The information was furnished, not filed, under the Exchange Act.
Hyperfine, Inc. (HYPR) reporting person Thomas Teisseyre, Chief Operating Officer and Director, reported a sale of Class A common stock on 08/18/2025. The Form 4 shows 1,151 shares were sold at $1.33 per share to satisfy tax withholding obligations tied to restricted stock units granted on March 28, 2022 and April 28, 2022. After the reported sale, Mr. Teisseyre beneficially owned 381,062 shares. The sale was executed under a "sell to cover" provision in the RSU agreement and the form was signed by an attorney-in-fact.